Quality of frozen transfusable plasma prepared from whole blood donations in Canada: An update

Transfusion and Apheresis Science

Volumn 49, Issue 3, 2013, Pages 440-446

  Sheffield, William P ^a,b,c   Bhakta, Varsha ^a,b   Talbot, Kimberley ^a,d   Pryzdial, Edward L G ^a,d   Jenkins, Craig ^a,b  

^a CANADIAN BLOOD SERVICES   (Canada)

^b Quality Monitoring Program   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Coagulation; Hemostasis; Plasma; Plasma quality; Solvent detergent plasma

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; FRESH FROZEN PLASMA; PROTEIN S; PROTHROMBIN;

ARTICLE; ASIA; BLOOD DONOR; CANADA; CONTROLLED STUDY; EUROPE; HUMAN; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PHLEBOTOMY; PLASMA TRANSFUSION;

COAGULATION; HEMOSTASIS; PLASMA; PLASMA QUALITY; SOLVENT/DETERGENT PLASMA;

BLOOD COMPONENT TRANSFUSION; BLOOD DONORS; BLOOD PRESERVATION; CANADA; FEMALE; FREEZING; HUMANS; MALE; PLASMA;

EID: 84888440245     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2013.06.012     Document Type: Article

References (39)

1. Guidelines for red blood cell and plasma transfusion for adults and children. Can Med Assoc J, vol. 156; 1997. p. S1-24.
2. Council of Europe: guide to the preparation, use and quality assurance of blood components: recommendation no. R (95) 15, 13th edition. Strasbourg: Council of Europe Publishing; 1997.
3. Expert Working Group Guidelines for red blood cell and plasma transfusion for adults and children. Can Med Assoc J, vol. 156; 1997. p. S1-24.
4. Roback J.D., Caldwell S., Carson J., Davenport R., Drew M.J., Eder A., et al. Evidence-based practice guidelines for plasma transfusion. Transfusion 2010, 50:1227-1239.
5. BCSH guidelines for the use of fresh frozen plasma (updated). Br J Haematol, vol. 126; 2004. p. 11-28.
6. Lawrie A.S., Cardigan R.A., Williamson L.M., Machin S.J., Mackie I.J. The dynamics of clot formation in fresh-frozen plasma. Vox Sang 2008, 94:306-314.
7. Fechtel K., Osterbur M.L., Kehrer-Sawatzki H., Stenson P.D., Cooper D.N. Delineating the Hemostaseome as an aid to individualize the analysis of the hereditary basis of thrombotic and bleeding disorders. Hum Genet 2011, 130:149-166.
8. Stanworth S.J., Hyde C.J., Murphy M.F. Evidence for indications of fresh frozen plasma. Transfus Clin Biol 2007, 14:551-556.
9. Stanworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology Am Soc Hematol Educ Program; 2007. p. 179-86.
10. Stanworth S.J., Brunskill S.J., Hyde C.J., McClelland D.B., Murphy M.F. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004, 126:139-152.
11. Yang L, Stanworth S, Hopewell S, Doree C, Murphy M. Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion; 2012.
12. Cardigan R., Lawrie A.S., Mackie I.J., Williamson L.M. The quality of fresh-frozen plasma produced from whole blood stored at 4°C overnight. Transfusion 2005, 45:1342-1348.
13. Runkel S., Haubelt H., Hitzler W., Hellstern P. The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood. Transfusion 2005, 45:427-432.
14. Yazer M.H., Cortese-Hassett A., Triulzi D.J. Coagulation factor levels in plasma frozen within 24h of phlebotomy over 5 days of storage at 1-6°C. Transfusion 2008, 48:2525-2530.
15. Serrano K., Scammell K., Weiss S., Culibrk B., Levin E., Gyongyossy-Issa M., et al. Plasma and cryoprecipitate manufactured from whole blood held overnight at room temperature meet quality standards. Transfusion 2010, 50:344-353.
16. Levin E., Culibrk B., Gyongyossy-Issa M.I., Weiss S., Scammell K., LeFresne W., et al. Implementation of buffy coat platelet component production: comparison to platelet-rich plasma platelet production. Transfusion 2008, 48:2331-2337.
17. Sheffield W.P., Bhakta V., Jenkins C., Devine D.V. Conversion to the buffy coat method and quality of frozen plasma derived from whole blood donations in Canada. Transfusion 2010, 50:1043-1049.
18. Vassallo R.R., Murphy S. A critical comparison of platelet preparation methods. Curr Opin Hematol 2006, 13:323-330.
19. Eder A.F., Sebok M.A. Plasma components: FFP, FP24, and thawed plasma. Immunohematology 2007, 23:150-157.
20. Sheffield W.P., Bhakta V., Mastronardi C., Ramirez-Arcos S., Howe D., Jenkins C. Changes in coagulation factor activity and content of di(2-ethylhexyl)phthalate in frozen plasma units during refrigerated storage for up to five days after thawing. Transfusion 2012, 52:493-502.
21. Doyle S., O'Brien P., Murphy K., Fleming C., O'Donnell J. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coag Fibrinolysis: An Int J Haemostasis Thrombosis 2003, 14:283-287.
22. Svae T.E., Frenzel W., Heger A., Romisch J. Quality differences between solvent/detergent plasmas and fresh-frozen plasma. Transfus Med 2007, 17:318-320. Author reply 21.
23. Heger A., Romisch J., Svae T.E. A biochemical quality study of a pharmaceutically licenced coagulation active plasma (Octaplas) thawed by the SAHARA-III dry tempering system compared to the regular use of a water bath. Vox Sang 2008, 94:48-55.
24. Favaloro E.J., Soltani S., McDonald J., Grezchnik E., Easton L. Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors. Blood Coagul Fibrinol 2005, 16:597-605.
25. Gallinaro L., Cattini M.G., Sztukowska M., Padrini R., Sartorello F., Pontara E., et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008, 111:3540-3545.
26. Kamal A.H., Tefferi A., Pruthi R.K. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 2007, 82:864-873.
27. Lu F.Q., Kang W., Peng Y., Wang W.M. Characterization of blood components separated from donated whole blood after an overnight holding at room temperature with the buffy coat method. Transfusion 2011, 51:2199-2207.
28. Madla W., Alt T., Jungk H., Bux J. Fresh frozen plasma quality: relation to age and gender of blood donors. Vox Sang 2012, 102:116-124.
29. Wilsher C., Garwood M., Sutherland J., Turner C., Cardigan R. The effect of storing whole blood at 22°C for up to 24h with and without rapid cooling on the quality of red cell concentrates and fresh-frozen plasma. Transfusion 2008, 48:2338-2347.
30. Chabanel A., Sensebe I., Masse M., Maurel J.P., Plante J., Hivet D., et al. Quality assessment of seven types of fresh-frozen plasma leucoreduced by specific plasma filtration. Vox Sang 2003, 84:308-317.
31. Kretzschmar E., Kruse F., Greiss O., Paunovic D., Kallweit T., Trobisch H. Effects of extended storage of whole blood before leucocyte depletion on coagulation factors in plasma. Vox Sang 2004, 87:156-164.
32. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 2004, 11:346-350.
33. Flesland O., Seghatchian J., Solheim B.G. The Norwegian Plasma Fractionation Project - a 12 year clinical and economic success story. Transfus Apheresis Sci: Off J World Apheresis Association: Off J Eur Soc Haemapheresis 2003, 28:93-100.
34. Jilma-Stohlawetz P., Kursten F.W., Walasek C., Horvath M., Leitner G., List J., et al. Safety of a universal, virus-inactivated and prion-depleted, pharmaceutical-quality plasma: a randomized, double-blind, clinical trial in healthy volunteers. Transfusion 2011, 51:1228-1240.
35. Buchta C., Felfernig M., Hocker P., Macher M., Kormoczi G.F., Quehenberger P., et al. Stability of coagulation factors in thawed, solvent/detergent-treated plasma during storage at 4°C for 6 days. Vox Sang 2004, 87:182-186.
36. Nifong T.P., Light J., Wenk R.E. Coagulant stability and sterility of thawed S/D-treated plasma. Transfusion 2002, 42:1581-1584.
37. Burnouf T., Goubran H.A., Radosevich M., Sayed M.A., Gorgy G., El-Ekiaby M. Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma. Biologicals 2007, 35:349-353.
38. Williamson L.M., Llewelyn C.A., Fisher N.C., Allain J.P., Bellamy M.C., Baglin T.P., et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999, 39:1227-1234.
39. Lerner R.G., Nelson J., Sorcia E., Grima K., Kancherla R.R., Zarou-Naimo C.M., et al. Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang 2000, 79:161-167.